FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – First Report: Final 5 Year Clinical Outcomes

Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of patients with any cardiovascular disease to include devices, drugs, and digital health care products listed below:

• Consultant Fee/Honoraria/Speaker's Bureau (Personal) - Abbott Vascular; REVA Medical
• Grant Support/Research Contract (Both) - Cardiac Dimensions